USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Celcuity Announces Launch of Revtopic and Third Quarter 2026 Financial Results

The Motley Fool · ·by G4L

CELC
CELC Celcuity Inc
$66.79 +4.29%
View chart & analysis →
  1. 1Celcuity reported the commercial launch of Revtopic on September 30.
  2. 2Since September 30, 78% of Celcuity's top 36 key strategic accounts have ordered Revtopic.
  3. 3Celcuity reported a net loss of $73.3 million for the third quarter of 2026.

So what's the key point?

Celcuity has released a new drug called Revtopic. Major hospitals are ordering the drug frequently, which creates anticipation for the future.

Source The Motley Fool · View original ↗

Related 3-line summaries

Celcuity Inc begins commercial transition with $1.33 per share loss in Q3 Earnings Whispers +1 · yesterdayCantor Fitzgerald sets $140 price target for Celcuity Investing.com · Oct 233 stocks with surging option volume following earnings releases Schaeffer's Research · 5h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news